Related Experiment Video
Updated: Aug 8, 2025
08:26
Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
Published on: January 21, 2020
6.8K
Development of a Novel Valve-Controlled Drug-Elutable Microstent for Microinvasive Glaucoma Surgery: In Vitro and
Stefan Siewert1, Sabine Kischkel2, Andreas Brietzke2
1Institute for ImplantTechnology and Biomaterials e.V., Rostock-Warnemünde, Germany.
Translational Vision Science & Technology
|March 1, 2023
Summary
This study developed a novel microstent for microinvasive glaucoma surgery (MIGS) that safely and effectively lowers intraocular pressure. Further research will explore drug-elutable coatings for enhanced glaucoma treatment.
Area of Science:
- Ophthalmology
- Biomedical Engineering
- Materials Science
Background:
- Microinvasive glaucoma surgery (MIGS) is crucial for primary open-angle glaucoma.
- Current MIGS implants lack satisfactory long-term intraocular pressure (IOP) control.
- A novel microstent aims to improve MIGS efficacy and safety.
Purpose of the Study:
- To develop and test a novel silicone elastomer microstent for MIGS.
- To evaluate the in vitro and in vivo performance of the microstent.
- To assess the potential for safe and effective IOP reduction in glaucoma management.
Main Methods:
- Silicone elastomer microstents were fabricated using dip coating, fs-laser cutting, and spray coating.
- In vitro testing included pressure-flow characteristics and biocompatibility assessments.
- In vivo studies involved implanting microstents in rabbits to evaluate IOP reduction and device stability.
Main Results:
- Successful in vitro characterization and manufacturing of the microstents.
- In vivo implantation showed successful IOP reduction in 75% of rabbits (4/6) with adequate device fixation.
- A 6-month trial demonstrated safe and effective IOP reduction in eyes with correctly implanted microstents.
Conclusions:
- The developed microstent shows promise as an innovative treatment for MIGS.
- Proof of concept for safe and effective IOP reduction was established in a preclinical setting.
- Future work will focus on incorporating antifibrotic drugs into the microstent coating.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
512
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
512
01:28Angle Closure Glaucoma: Treatment
602
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
602
01:26Mitral Stenosis III: Medical Management
16
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
16